Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 284, Issue 6 53-6, 2003, Pages

  Wang, Shujie ^a   Hasham, Muneer G ^a   Isordia Salas, Irma ^a   Tsygankov, Alexander Y ^a   Colman, Robert W ^a   Guo, Yan Lin ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Bradykinin; Cell cycle

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYCLIN A; DNA; HIGH MOLECULAR WEIGHT KININOGEN; PROTEIN KINASE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANNEXINS; APOPTOSIS; BLOTTING, WESTERN; CDC2 PROTEIN KINASE; CELL CYCLE; CELL SURVIVAL; CELLS, CULTURED; CYCLIN A; DNA; ENDOTHELIUM, VASCULAR; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; KININOGEN, HIGH-MOLECULAR-WEIGHT; TIME FACTORS; UP-REGULATION;

EID: 0038024651     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Beckner ME. Factors promoting tumor angiogenesis Cancer Invest 17: 594-623, 1999.
2. Browder T, Folkman J, and Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 275: 1521-1524, 2000.
3. Cao R, Wu HL, Veitonmaki N, Linden P, Farnebo J, Shi GY, and Cao Y. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 96: 5728-5733, 1999.
4. Cao Y, Chen A, An SSA, Ji RW, Davidson D, and Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 272: 22924-22928, 1997.
5. Chadebech P, Truchet I, Brichese L, and Valette A. Upregulation of Cdc2 protein during paclitaxel-induced apoptosis. Int J Cancer 87: 779-786, 2000.
6. Chavakis T, Kanse SM, Lupu F, Hammes HP, Muller-Esterl W, Pixley RA, Colman RW, and Preissner KT. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood 96: 514-522, 2000.
7. Choi KS, Eom YW, Kang Y, Ha MJ, Rhee H, Yoon JW, and Kim SJ. Cdc2 and Cdk2 kinase activated by transforming growth factor-β1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells. J Biol Chem 274: 31775-31783, 1999.
8. Colman RW, Jameson BA, Lin Y, Johnson D, and Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) downregulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 95: 543-550, 2000.
9. Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, and McCrae KR. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 100: 1481-1487, 1997.
10. Colman RW, Pixley RA, Sainz IM, Song JS, Isordia-Salas I, Muhamed SN, Powell JA, and Mousa SA. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high molecular weight kininogen. J Thromb Haemostas 1: 164-170, 2003.
11. Colman RW and Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90: 3819-3843, 1997.
12. Folkman J and Shing Y. Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
13. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, Perricaudet M, Yeh P, and Lu H. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 95: 6367-6372, 1998.
14. Guo YL, Kang B, Yang LJ, and Williamson JR. Tumor necrosis factor-α and ceramide induce cell death through different mechanisms in rat mesangial cells. Am J Physiol Renal Physiol 276: F390-F397, 1999.
15. Guo YL, Wang S, and Colman RW. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol 21: 1427-1433, 2001.
16. Konishi Y, Lehtinen M, Donovan N, and Bonni A. Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell 9: 1005-1016, 2002.
17. Lew DJ and Kornbluth S. Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol 8: 795-804, 1996.
18. Meikrantz W, Gisselbrecht S, Tam SW, and Schlegel R. Activation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci USA 91: 3754-3758, 1994.
19. Meikrantz W and Schlegel R. Apoptosis and the cell cycle. J Cell Biochem 58: 160-174, 1995.
20. Meikrantz W and Schlegel R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem 271: 10205-10209, 1996.
21. Morbidelli L, Parenti A, Donnini S, Granger HJ, Ledda F, and Ziche M. Differential contribution of bradykinin receptors in angiogenesis. Adv Exp Med Biol 476: 117-128, 2000.
22. Norbury C, MacFarlane M, Fearnhead H, and Cohen GM. Cdc2 activation is not required for thymocyte apoptosis. Biochem Biophys Res Commun 202: 1400-1406, 1994.
23. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
24. Parenti A, Morbidelli L, Ledda F, Granger HJ, and Ziche M. The bradykinin/B1 receptor promotes angiogenesis by upregulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 15: 1487-1489, 2001.
25. Porter LA, Singh G, and Lee JM. Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis. Blood 95: 2645-2650, 2000.
26. Shi L, Chen G, He D, Bosc DG, Litchfield DW, and Greenberg AH. Granzyme B induces apoptosis and cyclin A-associated cyclin-dependent kinase activity in all stages of the cell cycle. J Immunol 157: 2381-2385, 1996.
27. Thomas HC, Lame MW, Morin D, Wilson DW, and Segall HJ. Prolonged cell-cycle arrest associated with altered Cdc2 kinase in monocrotaline pyrrole-treated pulmonary artery endothelial cells. Am J Respir Cell Mol Biol 19: 129-142, 1998.
28. Vincent L, Soria C, Mirshahi F, Opolon P, Mishal Z, Vannier JP, Soria J, and Hong L. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 22: 623-629, 2002.
29. Weisel JW, Nagaswami C, Woodhead JL, DeLa Cadena RA, Page JD, and Colman RW. The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J Biol Chem 269: 10100-10106, 1994.
30. Ye K, Zhou J, Landen JW, Bradbury EM, and Joshi HC. Sustained activation of p34Cdc2 is required for noscapine-induced apoptosis. J Biol Chem 276: 46697-46700, 2001.
31. Zhang JC, Claffey K, Sakthivel R, Darzynkiewicz Z, Shaw DE, Leal J, Wang YC, Lu FM, and McCrae KR. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J 14: 2589-2600, 2000.